Ensysce Biosciences, Inc.

Listed Company

ENSCCIK 0001716947NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$5.07M

Net Income

$-10.18M

Total Assets

$7.45M

Equity

$3.21M

Shares Out

14.69M

Op. Cash Flow

$-7.81M

ENSC$0.29−86.54% · past yearDBEQ Basic

Daily closing prices

Business

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company developing prodrug technologies to improve the safety of prescription opioids and reduce abuse potential. Its lead product candidate, PF614, is a chemically modified oxycodone prodrug using the proprietary TAAP platform, designed to release active drug only in the gastrointestinal tract. The company is also developing PF614-MPAR, combining PF614 with nafamostat for overdose protection, and has extended its platform to abuse-resistant amphetamines.

Summary from 10-K filed 2026-03-30

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Federal grants	5	5	2	3	4
Research and development	10	7	8	20	5
General and administrative	5	5	5	7	19
Total operating expenses	15	12	13	27	23
Loss from operations	−10	−7	−11	−24	−20
Change in fair value of liability classified warrants	10,096	16,292	283,958	7	−1
Interest expense, net	−18,767	−1	−353,945	—	—
Other income and expense, net	73,430	17,277	15,420	86,223	−282,279
Total other income (expense), net	64,759	−1	91,912	14,410	−9
Net loss	−10	−8	−11	−24	−29
Net loss attributable to noncontrolling interests	−487	−74	−13,201	−35,393	−62,190
Deemed dividend related to warrants down round provision	—	290	12,937	913,204	803,140
Net loss attributable to common stockholders	−10	−8	−11	−25	−30
Net loss per share attributable to common stockholders, basic	−3.98	−11.45	−70.4	−139.42	−29.64
Net loss per share attributable to common stockholders, diluted	−3.98	−11.45	−70.4	−139.42	−1.48
Weighted average common shares outstanding, basic	3	697,686	150,937	179,925	1
Weighted average common shares outstanding, diluted	3	697,686	150,937	179,925	20

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	4	4	1	3	12
Unbilled receivable	420,345	124,115	97,561	276,821	441,721
Prepaid expenses and other current assets	3	2	1	2	—
Total current assets	7	5	2	5	16
Property and equipment, net	124,129	—	—	—	—
Other assets	85,882	252,550	419,217	585,883	754,756
Total assets	7	6	3	6	16
Accounts payable	3	1	2	3	301,104
Accrued expenses and other liabilities	993,411	548,458	542,260	2	3
Notes payable and accrued interest	306,708	301,660	854,697	4	13
Total current liabilities	5	2	3	9	16
Other long-term liabilities	—	10,096	26,388	310,346	—
Total long-term liabilities	—	10,096	26,388	450,494	8
Total liabilities	5	2	3	10	25
Commitments and contingencies (Note 7)	—	—	—	—	—
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, 4,000 shares issued, 3,305 shares outstanding, and $3,635,500 liquidation preference at December 31, 2025; no shares issued and outstanding at December 31, 2024	—	—	—	—	—
Common stock, $0.0001 par value, 250,000,000 shares authorized at December 31, 2025 and December 31, 2024; 4,574,983 and 1,355,779 shares issued at December 31, 2025 and December 31, 2024, respectively; 4,574,977 and 1,355,773 shares outstanding at December 31, 2025 and December 31, 2024, respectively	459	136	21	53	124
Additional paid-in capital	143	133	121	107	78
Accumulated deficit	−140	−130	−122	−111	−86
Total Ensysce Biosciences, Inc. stockholders equity	3	4	−322,858	−4	−8
Noncontrolling interests in stockholders deficit	−328,970	−328,483	−328,409	−315,208	−279,815
Total stockholders equity	3	3	−651,267	−4	−8
Total liabilities and stockholders equity	7	6	3	6	16

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Accrued interest	12,393	43,927	18,648	60,488	349,339
Amortization of original issue discount and debt issuance costs	—	1	326,151	—	—
Consultant compensation	668,682	—	—	—	—
Stock-based compensation	177,086	110,723	879,160	1	121,764
Depreciation expense	6,533	—	—	—	151
Unbilled receivable	−296,230	−26,554	179,260	164,900	−441,721
Prepaid expenses and other assets	−438,565	−251,965	1	2	−2
Accounts payable	2	−578,928	−1	3	−1
Accrued expenses and other liabilities	434,434	6,198	−1	1	2
Net cash used in operating activities	−8	−8	−11	−18	−8
Investment in property and equipment	−123,643	—	—	—	—
Net cash flows used in investing activities	−123,643	—	—	4,500	—
Proceeds from public offerings	1	2	9	4	—
Proceeds from warrant exercises	3	2	—	—	—
Proceeds from warrant inducement, net of issuance costs	2	8	—	—	—
Proceeds from issuance of Series B Preferred Stock	4	—	—	—	—
Transaction costs associated with public offering and warrant inducements	−501,214	−1	—	—	—
Transaction costs associated with Series B Preferred Stock issuance	−391,376	—	—	—	—
Repayment of convertible notes	—	−485,190	−1	−1	—
Repayment of financed insurance premiums	−216,284	−372,529	−451,668	−595,509	−488,543
Net cash provided by financing activities	9	10	9	9	20
Increase in cash and cash equivalents	808,277	2	−2	−9	12
State minimum tax payments	2,500	3,200	3,200	1,600	1,600
Incremental fair value of August 2024 Warrant Inducement	—	10	—	—	—
Incremental fair value of February 2024 Warrant Inducement	—	5	—	—	—
Incremental fair value of April 2025 Warrant Inducement	3	—	—	—	—
Transaction costs under accounts payable and accrued expenses	119,266	—	—	—	—
Investment in property and equipment under accounts payable	7,091	—	—	—	—
Conversion of convertible notes into common stock	—	1	3	18	—
Financed insurance premiums	188,046	232,155	445,737	400,000	867,300
Deemed dividend related to warrants down round provision	—	290	12,937	913,204	803,140

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Ensysce Biosciences, Inc.'s CIK number?

Ensysce Biosciences, Inc.'s SEC CIK number is 0001716947 (1716947). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Ensysce Biosciences, Inc.'s SEC filings?

All of Ensysce Biosciences, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Ensysce Biosciences, Inc. last report earnings?

Ensysce Biosciences, Inc. (ENSC) most recently filed an earnings 8-K with the SEC on May 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-023810). This is Ensysce Biosciences, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Ensysce Biosciences, Inc.'s most recent earnings 8-K?

Ensysce Biosciences, Inc.'s latest earnings 8-K (Item 2.02) was filed May 15, 2026 under accession 0001493152-26-023810. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Ensysce Biosciences, Inc.'s latest earnings 8-K →
Look up any company's CIK number →